Search for: "Mylan Pharmaceuticals v. FDA"
Results 141 - 160
of 233
Sorted by Relevance
|
Sort by Date
31 Oct 2008, 11:53 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Oxytrol (Oxybutynin) - US: Watson files patent infringement lawsuit against Barr over application to market generic Oxytrol; Barr challenges Oxytrol patent… [read post]
22 Dec 2010, 3:01 am
-Florida (Patent Docs) FazaClo (Clozapine): US – Patent infringement complaint filed following a Paragraph IV certification: Mylan Pharmaceuticals Inc. v. [read post]
29 Dec 2010, 2:57 am
Ferring Pharmaceuticals, Inc et al. [read post]
6 Jan 2010, 3:32 am
’ (The SPC Blog) India: Reviewing the Indian Patent Regime after 5 years of the introduction of the pharmaceutical product patent regime (Spicy IP) UK: Department of Health proposing generic prescription drugs option (GenericsWeb) US: 7th Circuit: Enforcing contracts between joint owners: Wisconsin Alumni Research Foundation (WARF) v. [read post]
9 Sep 2009, 7:14 am
(America-Israel Patent Law) Avinza (Morphine) – US: King Pharmaceuticals, Elan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Cipro (Ciprofloxacin) – US: California court rules that Bayer AG et al did not violate state antitrust law in Cipro reverse payment case (FDA Law Blog) Effexor (Venlafaxine) - Israel: Patent oppositions: should substance or procedural issues win out? [read post]
27 Jun 2011, 8:41 am
Amicus brief of Mylan Pharmaceuticals, Inc. [read post]
21 Sep 2011, 6:41 am
Mylan Bertek Pharmaceuticals, Inc., Civil No. 09-690 (JNE/JSM), 2010 WL 2519988 (D. [read post]
7 Feb 2008, 10:46 am
Rather, the two diverge when the plaintiff's interpretation of the relevant FDA requirement differs from how the FDA reads the same language. [read post]
20 May 2009, 5:18 am
’ (Patent Docs) Atripla/Truvada (Efavirenz, Emtricitabine, Tenofovir) – US: Gilead Sciences files second patent infringement lawsuit against Teva Pharmaceuticals over Emtricitabine, a component of Truvada and Atripla (SmartBrief) (The IP Factor) (GenericsWeb) Champix (Varenicline) – India: Pfizer responds to Dr Reddy’s post-grant opposition to Champix filed at Mumbai Patent Office (GenericsWeb) (Spicy IP) Corpril (Ramipril) – Hungary:… [read post]
15 Sep 2010, 2:40 am
KG v Apotex Pty Ltd (No 2) (Patentology) MoviPrep – US: Salix and Norgine settle with Novel in patent dispute over MoviPrep (Patent Docs) Nexavar (Sorafenib) – India: Nexavar patent infringement suit before Delhi HC goes directly to trial: Bayer v Cipla (Spicy IP) Simcor (Niacin/Simvastatin) – US: Abbott files patent infringement suit against Teva following Para IV challenge (Patent Docs) Vancocin (Vancomycin) – US: ViroPharma sues FDA over generic… [read post]
9 Dec 2009, 3:59 pm
Teva Pharmaceuticals USA Inc. [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period… [read post]
4 May 2011, 4:13 am
Purepac Pharmaceutical, et. al. [read post]
29 Jul 2010, 10:24 am
’s (“Caraco”) and Sun Pharmaceutical Laboratories, Ltd. [read post]
15 Feb 2011, 5:26 pm
(FDA Law Blog) Diovan (Vasartan) – France: Novartis v Actavis – preliminary injunction for Valsartan confirmed (The SPC Blog) Diovan HTC (Valsartan) – Belgium: Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog) Lescol (Fluvastatin) – US: Novartis files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (GenericsWeb)… [read post]
1 Dec 2010, 12:15 am
Abraxis Bioscience, Inc. v. [read post]
3 Aug 2011, 3:31 am
Patent and Trademark Office (Holman’s Biotech IP Blog) US: Myriad writes to CAFC on standing issue (Patent Docs) (Patent Docs) (Holman’s Biotech IP Blog) US: In the first 7 months of 2011, the FDA has approved 18 new molecular entity pharmaceutical drugs (and no biologic NMEs) (KEI) US: Embryonic stem cell funding suit dead: Sherley v. [read post]
8 Dec 2010, 2:20 am
(America-Israel Patent Law) Ziagen (Abacavir) – US: Mylan’s Matrix receives tentative FDA approval under PEPFAR for Abacavir Sulfate tablets, 60 mg (SmartBrief) [read post]
25 Nov 2009, 12:00 pm
Maharaja Appliances (Spicy IP) India: Harmonising the interpretation of ‘efficacy’ in section 3(d) with Article 27 of TRIPS – IPAB decision in Glivec case (Spicy IP) UK: Medeva pertussis vaccines fail the Art 3 test as question of appeal remains unresolved: Medeva BV’s application (The SPC Blog) US: Amicus briefs in Ariad v Eli Lilly (Patent Docs) (Patent Docs) (Patent Docs) (Patent Docs) US: Senate set to debate merged health care reform bill (FDA Law Blog)… [read post]
6 Jul 2011, 2:21 am
(Patent Baristas) US: FDA’s Chief Counsel, Ralph Tyler, set to leave FDA (FDA Law Blog) US: Docs at BIO: Steve Burrill’s state of the biotechnology industry report 2011 (Patent Docs) US: Counterfeiting: White House IP Czar Victoria Espinel on working with corporations (BIOtechNOW) US: Banning gene patents will promote innovation? [read post]
